Introduction
============

Glaucoma is a complex progressive neurodegenerative eye disease caused by genetic and environmental factors \[[@r1]\]. It is the leading cause of irreversible blindness worldwide. There are an estimated 57.5 million people worldwide with glaucoma \[[@r2]\]. It was estimated recently that there will be approximately 79.6 million people with glaucoma by 2020 \[[@r3],[@r4]\]. Based on anatomic changes in the anterior chamber angle, primary glaucoma may be classified as primary angle closure glaucoma (PACG) or primary open-angle glaucoma (POAG). POAG is the most common form of glaucoma which is clinically characterized by an open and normal anterior iridocorneal chamber angle and responsible for 74% of all glaucoma cases, affecting 1% to 2% of the population over age 40 \[[@r4]\]. POAG may be further subdivided into juvenile open‐angle glaucoma (JOAG) and adult onset POAG \[[@r5]\]. JOAG is an uncommon subset of POAG that differs from adult-onset POAG in the age of onset and often in the magnitude of intraocular pressure (IOP) elevation.

Family pedigree studies have indicated that some portion of glaucoma is inherited in a Mendelian pattern. Family-based genetic linkage analysis has identified many genomic loci associated with POAG, including GLC1A to GLC1P, and GLC3A \[[@r6],[@r7]\]. Several causative genes, such as *MYOC* (Gene ID 4653, OMIM [601652](https://www.ncbi.nlm.nih.gov/omim/?term=601652)) \[[@r8],[@r9]\], *OPTN* (Gene ID 10133, OMIM [602432](https://www.ncbi.nlm.nih.gov/omim/?term=602432)) \[[@r10]\], *WDR36* (Gene ID 134430, OMIM [609669](https://www.ncbi.nlm.nih.gov/omim/?term=609669)) \[[@r11]\], *CYP1B1* (Gene ID 1545, OMIM [601771](https://www.ncbi.nlm.nih.gov/omim/?term=601771)) \[[@r12],[@r13]\], *ASB10* (Gene ID 136371, OMIM [615054](https://www.ncbi.nlm.nih.gov/omim/?term=615054)) \[[@r14],[@r15]\], and *FOXC1* (Gene ID 2296, OMIM [601090](https://www.ncbi.nlm.nih.gov/omim/?term=601090)) \[[@r16]\] were discovered. To date, only 5--10% of POAG is attributed to single-gene or Mendelian forms of glaucoma \[[@r6]\]. Many of the other cases of POAG are likely due to the combined effects of several genetic and environmental risk factors. This indicates that many cases of POAG have a more complex genetic basis. In recent years, genome-wide association studies (GWASs) have been used to locate the genetic risk factors that contribute to the development of glaucoma. GWASs have demonstrated many genomic loci are associated with POAG risk, including *CDKN2B-AS1* (Gene ID 100048912, OMIM [613149](https://www.ncbi.nlm.nih.gov/omim/?term=613149)), *TMCO1* (Gene ID 54499, OMIM [614123](https://www.ncbi.nlm.nih.gov/omim/?term=614123)), *CAV1* (Gene ID 857, OMIM [601047](https://www.ncbi.nlm.nih.gov/omim/?term=601047)), *CAV2* (Gene ID 858, OMIM [601048](https://www.ncbi.nlm.nih.gov/omim/?term=601048)), *SIX1* (Gene ID 6495, OMIM [601205](https://www.ncbi.nlm.nih.gov/omim/?term=601205)), *SIX6* (Gene ID 4990, OMIM [606326](https://www.ncbi.nlm.nih.gov/omim/?term=606326)), *AFAP1* (Gene ID 60312, OMIM [608252](https://www.ncbi.nlm.nih.gov/omim/?term=608252)), *ABCA1* (Gene ID 19, OMIM [600046](https://www.ncbi.nlm.nih.gov/omim/?term=600046)), *TXNRD2* (Gene ID 10587, OMIM [606448](https://www.ncbi.nlm.nih.gov/omim/?term=606448)), *FOXC1/GMDS* (Gene ID 2762, OMIM [602884](https://www.ncbi.nlm.nih.gov/omim/?term=602884)), *ATXN2* (Gene ID 6311, OMIM [601517](https://www.ncbi.nlm.nih.gov/omim/?term=601517)), *FNDC3B* (Gene ID 64778, OMIM [61190](https://www.ncbi.nlm.nih.gov/omim/?term=61190)), ABO (Gene ID 28, OMIM [110300](https://www.ncbi.nlm.nih.gov/omim/?term=110300)), *PMM2* (Gene ID 5373, OMIM [601785](https://www.ncbi.nlm.nih.gov/omim/?term=601785)), *ATOH7* (Gene ID 220202, OMIM [609875](https://www.ncbi.nlm.nih.gov/omim/?term=609875)), *TMCO1* (Gene ID 54499, OMIM [614123](https://www.ncbi.nlm.nih.gov/omim/?term=614123)), and *GAS7* (Gene ID 8522, OMIM [603127](https://www.ncbi.nlm.nih.gov/omim/?term=603127)) \[[@r1],[@r6]\]. GWASs use single nucleotide polymorphism (SNP) markers to locate the new susceptibility gene; therefore, GWASs rarely identify functional or causal variants and cannot provide direct information on mutation patterns of susceptive genes. Mutation screening of the candidate genes is crucial for implicating the genes as the cause of a particular disease. Currently, several causative genes, such as *MYOC,* *OPTN, WDR36, CYP1B1, ASB10, FOXC1*, and *PITX2* (Gene ID 5308, OMIM [601542](https://www.ncbi.nlm.nih.gov/omim/?term=601542)), have been intensively analyzed by sequencing in different populations \[[@r8]-[@r12]\]. However, for the genes identified in GWASs, little information for variants detected in coding regions is available. Therefore, further research is needed to investigate whether these genes harbor pathogenically relevant rare coding variants and account for the observed association.

Recent advances in high-throughput sequencing technologies have dramatically improved the efficiency of screening for mutations in genes. Target sequencing for multiple candidate genes has become an important strategy for cost-effective detection of all possible mutations \[[@r17],[@r18]\]. In this study, we used molecular inversion probe (MIP)-based panel sequencing technology to identify rare coding variants associated with POAG. This technology enables high-throughput sequencing for coding regions of multiple candidate genes \[[@r18]\]. Furthermore, all steps of enriching the target area with an MIP can be performed in one test tube, so it is suitable for the screening of a large number of samples. In this study, a 26-gene panel were designed for analysis of the coding variants. This panel contained several POAG-causing genes, such as *MYOC*, *OPTN*, *WDR36*, *ASB10*, and *CYP1B1*, and many genes identified in GWASs or in association studies using the candidate-gene approach, such as *ABCA1, AFAP1, ABO, ATXN2, ATOH7, CAV1, CAV2, CDKN2B* (Gene ID 1030, OMIM [600431](https://www.ncbi.nlm.nih.gov/omim/?term=600431)), *LOXL1* (Gene ID 4016, OMIM [153456](https://www.ncbi.nlm.nih.gov/omim/?term=153456)), and *APOE* (Gene ID 348, OMIM [107741](https://www.ncbi.nlm.nih.gov/omim/?term=107741)). In addition, we included several candidate genes for research on their putative role in POAG, such as *LOXL1,* which has been reported with exfoliation glaucoma \[[@r19]\]; *EFEMP1,* which was identified by exon sequencing of families with POAG \[[@r20]\]; *PAK7* (Gene ID 57144, OMIM [608038](https://www.ncbi.nlm.nih.gov/omim/?term=608038)), which has shown copy number variation (CNV) in patients with POAG \[[@r21]\]; and *VRK2* (Gene ID 7444, OMIM [602169](https://www.ncbi.nlm.nih.gov/omim/?term=602169)), which is located in 2p15-p16 which was associated with POAG in a previous study we conducted \[[@r22]\]. By applying this panel, we performed the identification of potentially disease-relevant variants (PDVs) in 235 Han Chinese patients with POAG and 241 controls. We identified numerous variants of interest for further analysis.

Methods
=======

Sample collection
-----------------

This study was approved by the ethics committee of Daping Hospital of the army medical university. All experimental procedures were conducted in accordance with the Association for Research in Vision and Ophthalmology (ARVO) statement on human subjects. All participants signed an informed consent form before participating in the study in accordance with the provisions of the Declaration of Helsinki. A total of 235 patients with POAG and 241 unrelated control subjects without glaucoma were recruited at the Third Affiliated Hospital (Daping Hospital) of the Army Medical University from January 2018 to December 2018. All patients were assigned a study identity number that was known only to the ophthalmologist in the researcher group. These numbers were subsequently converted to linked study identities such that others could not access patients' private information. All human samples were linked to the study identities and barcoded, anonymized, and tracked in a centralized database, which was overseen by the researchers.

Most of the 235 patients are sporadic cases except the one set of siblings reported in this study (Appendix 1). All patients were Han Chinese. Patients with POAG were diagnosed by glaucoma specialists and fulfilled the following diagnostic criteria: open angles on gonioscopy (Grade 3 or 4 in Shaffer classification); presence of glaucomatous optic disc changes, including high cup-disc ratios (CDRs were estimated by one experienced doctor (T.L.) under ophthalmoscopy), disc ratio asymmetry between eyes (\>0.2), vertical elongation of the cup, focal neuroretinal rim thinning or notching, beta-zone peripapillary atrophy; abnormal circum papillary retinal nerve fiber layer (RNFL) thickness (cpRNFLT) in at least one clockwise optical coherence tomography (OCT) scan sector between 6, 7, 8, 10, 11, and 12 o'clock (6, 5, 4, 2, 1, and 12 o'clock in the left eye), confirmed in at least three examinations; visual field abnormalities, including localized defects respecting the horizontal meridian, nasal step, arcuate scotoma; and abnormal standard automated perimetry (SAP) tests were defined as pattern standard deviation (PSD) outside 95% normal confidence limits, or glaucoma hemifield test (GHT) outside normal limits (Humphrey, Zeiss, Germany), confirmed in at least two examinations. Exclusion criteria were the following: finding of secondary glaucoma (exfoliation syndrome, etc.) and any other ocular or systemic disease that could affect the optic nerve or the visual field.

The 241 unrelated control subjects ranged in age from 38 to 78 years, average age 63.7, and were confirmed without glaucoma symptoms. The clinical details of the 235 patients and the 241 control subjects are summarized in [Table 1](#t1){ref-type="table"} (for more information, also see Appendix 1 and Appendix 2).

###### Demographic and clinical features of the study subjects.

  Demographic/clinical features   POAG           With-PDVs    without-PDVs   P value    Controls        With-PDVs   Without-PDVs   p- value
  ------------------------------- -------------- ------------ -------------- ---------- --------------- ----------- -------------- ----------
  N (M/F)                         235(114/121)   66 (28/38)   169 (86/83)    \-         241 (111/130)   19(11/8)    222(100/122)   \-
  Age\* (years)                   52.7±14.5      44.8±14.6    55.8±13.2      5.37E-07   63.7±6.9        65.3±6.0    63.5±7.0       0.2527
  Age range                       17--79         17--75       17--79         \-         43--78          47--75      43--78         \-
  ≤40 years (N)                   50             27           23             1.26E-05   0               0           0              1
  40--60 years (N)                91             26           65             1          76              3           73             0.1965
  ≥60 years (N)                   94             13           81             5.81E-05   165             16          149            0.1965
  IOP (mmHg)                      25.6±10.1      26.5±9.9     25.3±10.2      0.4062     14.8±2.1        14.8±2.8    13.7±1.9       0.0812
  cup-disc ratio                  0.70±0.21      0.72±0.22    0.69±0.20      0.3366     0.28±0.04       0.27±0.05   0.29±0.04      0.2989
  Mean RNFLT                      64.1±11.9      63.5±10.6    64.3±12.4      0.5904     105.2±8.0       106.4±7.3   105.1±8.1      0.4931
  Mean Defect                     −16.4±9.1      −14.9±9.9    −16.9±8.6      0.1349     −2.4±0.9        −2.3±0.9    −2.4±0.9       0.761

\*Age at diagnosis for POAG patients or age at participating the project for control subject.

MIP design
----------

Twenty-six candidate genes were chosen for mutation screening in the patients with POAG. The candidate genes are listed in Appendix 3, and previous studies are summarized in Appendix 3. A total of 684 MIP oligonucleotides were designed to cover 314 exons (Appendix 4). The target DNA size was about 54 K bases. The MIPs were manually designed to capture the coding regions and 20- to 50-bp flanking regions of the exons of the target genes. The general structure for the MIP is a common 41-bp linker flanked by an extension and a ligation arm of 16 to 28 bp. The extension and ligation arms were designed with Tm of 57--62 °C. The MIP targets a specific 120--140 bp genomic region for gap-fill and circularization.

Target capture
--------------

Individual MIPs were column synthesized (SBS Genetech, Beijing, China). MIP capture experiments were performed with some modifications as previously described \[[@r18]\]. In briefly, a total of 684 probes were pooled and phosphorylations were performed with ATP and Polynucleotide Kinase (NEB, Beijing, China). Pooled probes used as a master probe mix. The genomic DNA was sheared into 300-500 bp by Bandelin sonorex AK 102 sonicator (Bandelin, Berlin, Germany) and then MIPs were added to hybridization mixture (300 ng fragmented DNA, 1× Ampligase buffer). Hybridization procedure was conducted as fellows: 94 °C for 2 min, 54 °C for 36 h. And then gap filling-in reaction was conducted as fellows: 0.3 μl Phusion DNA polymerse (NEB), 0.6 μl Ampligase (Epicentre, Madison) and 0.1 μM dNTP (NEB) was added for filling-in the gap at 54 °C for 3 h. To degrade un-circularized DNA, 0.5 μl Exonuclease I (NEB) and 0.5 μl Exonuclease III (NEB) was added to reaction mixture at 37 °C for 45 min, and then exonucleases were inactivated at 94 °C for 4 min.

Amplification and sequencing of the target library
--------------------------------------------------

Five microliters of circularized DNA was used for amplification in a 25-μl reaction containing 0.1 μM of the truncated PE1.0 primer and the PU primer with the Illumina adaptor sequence, 0.6 U of Phusion DNA polymerase, 200 μM of each dNTP, and 1X Phusion Master Mix. The first round of PCR was performed at 98 °C for 30 s, 13 cycles of 98 °C for 10 s, 57 °C for 30 s, 72 °C for 15 s, and finally 72 °C for 5 min. Then 5-μl reaction mixture containing 0.5 μM Illumina PE1.0 primer and sample index primer was added to the first-round PCR mixture to perform an additional PCR at 98 °C for 30 s, 13 cycles of 98 °C for 10 s, 59 °C for 30 s, 72 °C for 15 s, and finally, 72 °C for 5 min (primer sequences are listed in Appendix 4). Barcoded libraries were pooled together and purified with 0.8X AMPure XP beads (Beckman Coulter, Brea, CA) to remove the primer dimers. The purified library was sent for sequencing of 2X 150-bp paired-end reads on Illumina Hiseq X-Ten (San Diego, CA).

Sequencing data analysis and variant identification
---------------------------------------------------

Before alignment, low-quality reads were removed with filtering. All reads were aligned to the human reference genome (GRCh37/hg19) using the Burrow Wheeler Aligner (BWA)-Smith Waterman (SW) algorithm from BWA software version 0.7.15, with all alignment parameters set to default values. Resulting alignments were processed and converted to the BAM format with SAMtools software version 0.1.18.22. The sequence variants were called by the GATK and Picard programs (<https://software.broadinstitute.org/gatk/>) and further annotated by [wAnnovar](http://wannovar.wglab.org) and Ensembl Variant Effect Predictor ([VEP](http://grch37.ensembl.org/info/docs/tools/vep/index.html)). Sequence alignments at variant positions were manually inspected using Integrative Genomics Viewer (IGV) software version 2.3.90. An average of about 0.2 Gb per sample (range 0.1--0.4 Gb per sample) of high-quality sequences was obtained. In this study, several optimizations were employed to improve the efficiency and uniformity of capture of the MIPs (Appendix 5). The approach achieved a high on-target specificity that about 91% of total reads can be mapped to the target regions. Targeted sequencing yielded median about 1,000-fold coverage; 98.4% of bases had \>50-fold coverage. Twelve variants were selected for confirmation, and all showed agreement with the results with Sanger sequencing (Appendix 5).

We selected rare variants for further analysis that met the following criteria: i) The variant was present in sequence reads from both strands, and the sequencing depth at the variant was more than 30; ii) the variant had a minor allele frequency (MAF) \<0.01 in the 1000 Genomes Project database (variants with minor allele frequency \<0.03 in the East Asian populations of Exome Aggregation Consortium (ExAC_EAS) were filtered out); iii) the variant represents at least 20% of the sequence reads at a particular site; and vi) all synonymous variants were not included.

In order to identify the PDVs from the identified rare variants (Appendix 6 and Appendix 7), we adopted the analysis procedure used in the previous literature to filter variants \[[@r23],[@r24]\]. The variants that occurred in the control group and did not reach a statistically significant difference (p\>0.05) between the patient and control groups were excluded. Variants, such as nonsense, frame-shift, canonical ± one or two splice sites, stop codon loss, deletion, and initiation codon loss, were included \[[@r25]\]. Two in silico tools, PolyPhen2 \[[@r26]\] and Sorting Intolerant From Tolerant (SIFT) \[[@r27]\], which have been recommended for aiding in the interpretation of sequence variants \[[@r25]\], were used to predict potentially deleterious effects of the variants. We filtered out the missense variants that were considered to be "tolerated" or "deleterious with low confidence" by SIFT, and were considered to be "benign" or "possibly damaging" by PolyPhen2 HVAR. Missense variants predicted to be deleterious by either SIFT or PolyPhen2 HVAR were included. Two in-frame deletion mutations predicted to be neutral by SIFT-Indel were also excluded. Five variants also occurred in the Han Chinese population in the 1000 Genomes Project (including 103 individuals of Han Chinese in Beijing (HCB) and 105 South Han Chinese (SHC), Appendix 8) and did not reach statistically significant difference were also excluded. Visualization of protein lollipop structures was performed by using [MutationMapper](https://www.cbioportal.org).

Statistical analysis
--------------------

The frequencies of PDV carriers between patients with POAG and controls in each gene were compared with Fisher's exact test. The clinical features of the study subjects including age at diagnosis (years), IOP, cup-disc ratio, mean RNFLT, and mean defect between the group with PDV and without PDV in the patients and controls were statistically analyzed using the Welch two-sample *t* test, all p values were based on two-tailed statistically analyses, and p values less than 0.05 were considered statistically significant. All analyses were performed with [R version 3.5.1](https://www.r-project.org/).

Results
=======

In this study, 235 patients with POAG and 241 controls were included for variant analysis. The demographic and clinical characteristics of the participants are shown in [Table 1](#t1){ref-type="table"}. Overall, the mean age of the control group was older than that of the patient group, considering the possible association between the onset of POAG and the age of the individuals. Control individuals were carefully checked to exclude those with any symptoms of POAG. We selected 26 candidate genes for identification of PDVs in POAG based on previous studies (Appendix 3). These candidate genes were chosen for target sequencing analysis as they were reported to be involved in the etiology of eye diseases or were reported to be associated with POAG by GWASs. We analyzed the coding regions for these candidate genes by using MIP-based target sequencing. The workflow of the MIP-based assay is shown in [Figure 1](#f1){ref-type="fig"}.

![Design of molecular inversion probe and MIP-based target-sequencing workflow. **A**: Molecular inversion probe (MIP) structure and design for regions of interest. The general structure for the MIP is a common 41-bp linker flanked by a target-specific extension and a ligation arm of 16 to 28 bp. **B**: MIP-based target-sequencing workflow. (i) Genomic DNA was sheared into 300--500 bp fragments. (ii) Pooled probes are added to the genomic DNA, and each probe is hybridized to the target DNA sequences through the target-specific sequences on both ends. (iii) The gaps are filled and circularized with DNA polymerase and ligase. (iv) The linear genomic DNA and uncircularized padlock probes are removed with exonuclease. (v) The circularized probes are amplified with a universal sequencing primer and a sample barcode primer.](mv-v26-378-f1){#f1}

Two filters were mainly used for identifying the PDVs: allele frequency and in silico tools' predictions of variants. We found 180 rare variants in 143 individuals among 235 patients with POAG and 57 rare variants in 94 individuals among 241 control subjects in coding regions of 26 genes (MAF\<0.01, Appendix 6 and Appendix 7). All rare variants identified are heterozygous. Twenty-two rare variants were present in patients with POAG and the controls. However, no statistically significant differences for these 22 rare variants in the allele frequencies were found between the patient and control groups (p\>0.11, Fisher's exact test). After further filtering (see Methods), we identified 82 PDVs and 18 PDVs in the patients with POAG and the controls, respectively ([Table 2](#t2){ref-type="table"}, detailed information was shown in Appendix 9 and Appendix 10). Of the 235 patients with POAG evaluated, 66 (28.1%) had at least one PDV in the candidate genes. In comparison, 19 of 241 subjects harbored PDVs in the control group, indicating an enrichment of PDVs in the POAG cohort (28.1% versus 7.9%, p = 8.629e-09, Fisher's exact test; Appendix 9).

###### The potentially disease-causing variants (PDVs) in POAG as compared with control.

  Gene     No. with PDVs in POAG (n=235)   No. with PDVs in control (n=241)   p**-value**   Odds Ratio Cases:Cont (95% Cl)
  -------- ------------------------------- ---------------------------------- ------------- --------------------------------
  ABCA1    6 (2.6)                         7 (3.0)                            1             0.88 (0.24-3.10)
  ABO      2 (0.9)                         0 (0)                              0.4989        \-
  AFAP1    3 (1.3)                         0 (0)                              0.1203        \-
  APOE     4 (1.7)                         1 (0.4)                            0.211         4.14 (0.41-205.29)
  ASB10    3 (1.3)                         2 (0.9)                            1.5439        0.58 (0.18-18.63)
  ATXN2    8 (3.4)                         0 (0)                              0.0033        \-
  CDKN2B   5 (2.1)                         0 (0)                              0.0287        \-
  CYP1B1   1 (0.4)                         1 (0.4)                            1             1.03 (0.01-80.79)
  EFEMP1   5 (2.1)                         1 (0.4)                            0.1184        5.20 (0.58-247.49)
  FNDC3B   4 (1.7)                         0 (0.4)                            0.0586        \-
  FOXC1    6 (2.6)                         0 (0.4)                            0.014         \-
  GAS7     5 (2.1)                         1 (0.4)                            0.1184        5.20 (0.58-247.49)
  LOXL1    6 (2.6)                         1 (0.4)                            0.0648        \-
  MYOC     6 (2.6)                         0 (0)                              0.014         \-
  OPTN     2 (0.9)                         2 (0.9)                            0.6195        1.03 (0.11-121.95)
  PAK7     3 (1.3)                         2 (0.9)                            0.6235        0.68 (0.18-18.63)
  PAX6     2 (0.9)                         1 (0.4)                            0.6195        2.06 (0.11-121.95)
  PITX2    4 (1.7)                         0 (0.4)                            0.0586        \-
  TMCO1    1 (0.4)                         0 (0)                              0.4937        \-
  TXNRD2   8(3.4)                          1 (0.4)                            0.019         7.34 (0.1-376.19)
  WDR36    3 (1.3)                         1 (0.4)                            0.3672        3.10 (0.25-163.45)

The odds ratio is calculated from the ratio of cases with and without PDVs in each gene in cases divided by the corresponding ratio in controls. P-values were calculated using a two-sided Fisher\'s Exact Test.

Of the 82 PDVs, there were five known deleterious missense mutations that were reported in previous studies, including p.Gln337Arg \[[@r28]\], p.Gln368Ter \[[@r29]\], and p.Pro370Leu in *MYOC* \[[@r30]\], p.Leu107Val in *CYP1B1* \[[@r31]\], and p.Arg130Trp in *PITX2* \[[@r32]\]. Thus, most of the PDVs identified in this study are novel. Insertions and deletions in the gene-coding regions, stop gain or loss, and variants located at the essential splice site sequences were generally considered to be more likely pathogenic \[[@r25]\]. We found eight such mutations in the POAG cohort, including three truncating mutations (p.Arg272Ter and p.Gln368Ter in *MYOC*, and p.Tyr848Ter in *FNDC3B*), four frame-shift mutations (p.(Asp677fs) in *ABCA1*, p.(Ser267fs) in *APOE*, p.(Gly77fs) in *CDKN2B* and p.(Gly453fs) in *FOXC1*), and a stop-loss mutation p.Ter494Glu in *EFEMP1* in the POAG cohort. Only one control subject harbored such a deleterious mutation (*ABCA1* p.Asp1894Efs) (3.4% versus 0.4%, p = 0.019, Fisher's exact test). Of the 82 PDVs, 74 PDVs were missense PDVs. All PDVs identified in the POAG cohort have low frequencies in the population (\<0.3% in ExAC_EAS and 1000 Genome Project database). Four of 82 PDVs were found in two or more patients (*ATXN2* p.Arg939Gln, three cases; *TXNRD2* p.Gly290Val, three cases; *EFEMP1* p.Leu451Pro, two cases; *PAK7* p.Gly310Glu, two cases). However, there was no statistically significant difference in the frequency for each recurrent PDV between the patient group and the control group (p\>0.12, Fisher\'s exact test).

PDVs were identified in 21 genes among 26 candidate genes for the POAG cohort, including *ATXN2* (six PDVs \[7.3% of total PDVs\]), *ABCA1* (six \[7.3%\]), *FOXC1* (six \[7.3%\]), *LOXL1* (six \[7.3%\]), *MYOC* (six \[7.3%\]), *TXNRD2* (six \[7.3%\]), *CDKN2B* (five \[6.1%\]), *GAS7* (five \[6.1%\]), *APOE* (four \[4.9%\]), *EFEMP1* (four \[4.9%\]), *FNDC3B* (four \[4.9%\]), and *PITX2* (four \[4.9%\]; Appendix 10). Of the 26 genes analyzed, five genes (*ATOH7, SIX6, VRK2, CAV1*, and *CAV2*) had no PDVs in the POAG cohort. Among the 26 candidate genes, the prevalence rate of PDVs in five genes showed a statistically significant difference between the patients and controls, including *ATXN2* (n = 8, 3.4%, p = 0.0033), *TXNRD2* (n = 8, 3.4%, p = 0.0190), *MYOC* (n = 6, 2.6%, p = 0.0140), *FOXC1* (n = 6, 2.6%, p = 0.0140), and *CDKN2B* (n = 5, 2.1%, p = 0.0287). Thirty-three patients harbored PDVs in these five genes, accounting for 50% of the total patients harboring PDVs. In comparison, only one subject with one PDV in these five genes was found in the control group (33/235 versus 1/241, p = 4.533e-10, Fisher's exact test).

Some patients (17 of 66 patients) harbored more than one PDV. For example, five patients with *FOXC1* PDVs also had an additional PDV in *ABCA1, ABO, GAS7*, and *EFEMP1* or two additional PDVs in *AFAP1* and *LOXL1* (Appendix 1). One patient had two different PDVs in *ATXN2* (p.R939Q and p.S1186I). But whether the two PDVs derived from different alleles is unclear. We analyzed the difference in diagnosis age, IOP, cup-to-disc ratio, mean defect, and mean RNFLT between patients with one PDV and patients with additional PDVs. However, no difference was found in these clinical features.

*MYOC* is a well-established POAG-causing gene, with a high prevalence rate in patients with POAG, as reported in a previous study \[[@r23]\]. In this study, we found six patients harboring six *MYOC* PDVs, accounting for up to 2.6% of all cases, which is slightly lower than previously reported (2.6% versus 4.6%) \[[@r9]\]. Before filtering against the variants observed in the controls, there were 31 patients harboring rare variants in *MYOC* (an MAF\<0.01 in the 1000 Genome Project database), representing the highest rate in the POAG cohort. However, several rare variants also occurred in control subjects. For example, p.Gln19His in *MYOC* has been reported in a previous study \[[@r9]\], which was found in three patients in this POAG cohort and two controls. Furthermore, p.Gln19His was found in three individuals among 208 Chinese individuals in the 1000 Genome Project population (see Appendix 8). These data indicated that p.Gln19His could be considered a polymorphism in the Chinese population. Homozygous p.Arg46Ter in *MYOC* was reported to be pathogenic \[[@r33]\]. Yoon et al. found a homozygous mutation p.Arg46Ter in a Korean patient with JOAG at age 15 years old \[[@r33]\]. In that report, the homozygote with this mutation was severely affected while the father, mother, and a sister were heterozygous for the mutation, apparently without detectable symptoms. This indicated that biallelic inactivation would result in a disease phenotype. In the present study, p.Arg46Ter of *MYOC* occurred in seven patients with POAG and in two control subjects (p = 0.10, Fisher's exact test). These results supported that the heterozygous p.Arg46Ter is a benign variant. Thus, only six PDVs in *MYOC* were identified after filtering. Among these six PDVs, a truncating mutation (p.Arg272Ter), has not been reported in a previous report. We did not find p.Arg272Ter in the EXAC_EAS or 1000 Genomes Project population. We speculated that p.Arg272Ter may be a disease-causing mutation.

In the *WDR36* gene, three PDVs (p.Arg95Gly, p.Ala147Thr, p.Pro780Leu; 1.3%) were found in patients. We found that two *WDR36* rare variants, p.Leu240Val and p.Ile713Val, occurred in patients and control subjects (two subjects for p.Leu240Val and three subjects for p.Ile713Val in the patient group; four subjects for p.Leu240Val and six subjects for p.Ile713Val in the control group). Thus, these two variants may be benign. Only two patients with POAG harbored *OPTN* PDVs (p.E230G and p.Val498Asp). This low prevalence rate is comparable with that in other studies on *OPTN* \[[@r23]\].

Investigating whether PDVs occur in the active sites of proteins may be useful to evaluate the influence of alternations on protein function. Locations of PDVs and domains in proteins are shown by lollipop structures ([Figure 2](#f2){ref-type="fig"}). We found several PDVs occurred in the active site of the encoded protein. For *MYOC*, previous studies have demonstrated that most mutations are located in the third exon, which codes for the olfactomedin (OLF)-like domain. The OLF domain contains a high-affinity calcium binding site with a five-bladed β-propeller structure \[[@r34]\]. In this study, we found that all six PDVs identified in the POAG group occurred in the OLF domain, and most were located within or near the calcium binding site. *FOXC1* is a DNA-binding transcriptional factor that is involved in eye development \[[@r35]\]. We found a patient harboring p.Tyr115His in *FOXC1*, which is located in DNA binding sites of *FOXC1* ([Figure 2](#f2){ref-type="fig"}). We deduced that p.Tyr115His may have a strong effect on DNA binding of the transcription factor, which would influence the expression of downstream target genes of *FOXC1*. We found a PDV (p.Cys448Phe) occurred in the *LOXL1* protein lysyl oxidase domain. Cys448 may be a conserved residue because the 443--456 sites are conserved in this domain, and several copper ion binding sites (His449, His451, and H453) are located in this region. Furthermore, Cys448 and Cys497 will form a disulfide bond. The mutation p.Cys448Phe may break the S--S bond. Thus, these variants have a higher probability of damaging the functional impact. The discovery of these PDVs in active sites also provided interesting targets for engineering relevant animal models of glaucoma.

![Locations of PDVs and domains in proteins of nine genes are shown by lollipop structures. Sites F114, Y115, N124, R127, H128, and K148 as DNA binding sites are shown with a red line in the forkhead domain of *FOXC1* (UniProt/Q12948). Copper ion binding sites (His449, His451, and H453) located in the lysyl oxidase domain of *LOXL1* are shown with a green line (Uniprot/Q08397). Sites D380, N428, A429, I477, and D478 as calcium ion binding sites are shown with a blue line in the olfactomedin (OLF) domain of *MYOC* (Uniprot/Q99972).](mv-v26-378-f2){#f2}

To investigate whether the PDVs influence the symptom of POAG, we analyzed the association between PDVs and clinical features of patients with POAG. There were 66 individuals with PDVs and 169 individuals without PDVs in the patient group ([Table 1](#t1){ref-type="table"}). The differences in the clinical features between subjects with PDVs and without PDVs were evaluated with a *t* test. No statistically significant difference in the IOP, cup-to-disc ratio, and mean RNFLT were observed between the two groups. We found an association between the presence of PDVs and age at diagnosis (mean of patients with PDVs = 44.8 years, mean of patients without PDVs = 55.8 years, p = 5.37e-07, Welch two-sample *t* test). When classifying patients by age, we found that PDVs were enriched in the subgroup of patients younger than 40 years of age (p = 1.26e-05, Fisher's exact test). It suggests probably a fraction of the PDVs contribute to the development of POAG disease and result in an earlier age of onset for glaucoma. A slight difference in the mean defect was also found (p = 0.1349, Welch two-sample *t* test), indicating that the symptom of the group without PDVs is slightly more severe than that of the group with PDVs. This might be explained by the fact that the subgroup without PDVs is older.

Discussion
==========

Glaucoma is a progressive degenerative condition, and the underlying mechanisms of glaucoma are not well understood. It has been suggested that glaucoma is a complex, multifactorial disease affected by genetic factors and environment \[[@r6],[@r36]\]. Discovery of the potentially disease-relevant variants will facilitate the research of POAG etiology. To discover PDVs in coding regions in a POAG cohort, we developed an MIP-based target sequencing for multiplex genes. This parallel screening for multiple target genes could provide a comparison in their prevalence rate. We found several genes with high prevalence rates that have not been reported in previous studies. Among 26 genes, *TXNRD2* (n = 8, 3.4%) and *ATXN2* (n = 8, 3.4%) had the highest frequency in the POAG cohort, followed by *MYOC* (n = 6, 2.6%), *FOXC1* (n = 6, 2.6%), *LOXL1* (n = 6, 2.6%), *ABCA1* (n = 6, 2.6%), *EFEMP1* (n = 5, 2.1%), *CDKN2B* (n = 5, 2.6%), and *GAS7* (n = 5, 2.1%; [Table 2](#t2){ref-type="table"}). In particular, we found that five genes, including *TXNRD2*, *ATXN2*, *FOXC1*, *MYOC*, and *CDKN2B*, reached a statistically significant difference between the patient group and the control group. We found that a substantial fraction of PDVs occurred in those genes identified in GWASs, such as *TXNRD2*, *ATXN2*, *FOXC1*, and *CDKN2B*. The *TXNRD2* gene encodes a mitochondrial protein that is involved in the control of reactive oxygen species levels and the regulation of mitochondrial redox homeostasis \[[@r37]\]. Oxidative stress is known to cause retinal ganglion cell (RGC) dysfunction in glaucoma models and clinical glaucoma samples. TXNRD2 regulates the cellular redox environment by scavenging reactive oxygen species in mitochondria \[[@r37]\]. The gene *Ataxin 2* (*ATXN2*) encodes a membrane protein located in the endoplasmic reticulum (ER) and plasma membrane (PM). This protein is involved in endocytosis and modulates mTOR signals that modify ribosomal translation and mitochondrial function \[[@r38]\]. *FOXC1* is a DNA-binding transcriptional factor that plays a role in a broad range of cellular and developmental processes, such as eye, bones, cardiovascular, kidney, and skin development \[[@r35]\]. Mutations in *FOXC1* have been associated with Axenfeld-Rieger (AR) syndrome, a disorder characterized by anterior segment malformations in the eye and glaucoma \[[@r39]\]. A GWAS was performed to identify new susceptibility loci of POAG, and three top SNPs were identified: rs35934224 \[T\] within TXNRD2; rs7137828 \[T\] within *ATXN*2, and rs2745572 \[A\] upstream of *FOXC1* \[[@r40]\]. This study identified new risk loci for POAG. However, whether these candidate genes harbor pathogenically relevant rare coding variants and account for the observed association require further investigation. The present data indicated a high prevalence of potentially pathogenic variants in *TXNRD2* (3.4%), *ATXN2* (3.4%), and *FOXC1* (2.6%) in patients with POAG, providing direct evidence to support the three genes involved in POAG. Furthermore, we found a PDV p.Tyr115His is located in DNA binding sites of *FOXC1* protein that would has a strong influence on protein function. Altogether, these results indicated that a fraction of PDVs may have functional impact on POAG risk loci.

This study indicated that *EFEMP1* might be involved in POAG. Four PDVs of *EFEMP1* were observed in six patients with POAG. Specifically, a stop-loss mutation p.Ter494Glu was found in two sisters with POAG ([Figure 3](#f3){ref-type="fig"}). This stop-loss mutation results in the production of an abnormal protein that is 29 amino acids longer than expected, which may have an impact on its protein function. The siblings also harbored a rare variant p.Arg387Gln in *EFEMP1.* The siblings received a diagnosis of POAG at the age of 21 and 23 years old, respectively. Both exhibited severe visual-field loss in the right eye. Their father also had POAG and was diagnosed at 43 years old. Their mother has not shown any detectable symptoms. Further analysis showed that their father harbored p.Ter494Glu, and their mother harbored p.Arg387Gln ([Figure 3](#f3){ref-type="fig"}). As their father has shown POAG symptoms, we deduced that p.Ter494Glu is the potentially causative mutation for this family. Their mother has p.Arg387Gln, and she does not show any POAG symptoms yet. The missense *EFEMP1* p.Arg387Gln occurred in six patients and eight control subjects, suggesting it might be a normal SNP. The *EFEMP1* gene was located within the GLC1H locus on chromosome 2p (2p15-p16). Although there have been a few efforts to confirm the link to GLC1H, it remains uncertain \[[@r41]\]. It is expressed in the retina and RPE, involved in age-related macular degeneration (AMD) \[[@r42],[@r43]\]. A GWAS identified copy number variation (CNV) at *NPHP1* and *EFEMP1* as potential candidates for association of inherited retinal degenerative diseases \[[@r44]\]. A report located a genetic locus (GLC1H) for adult-onset POAG maps to the 2p15-p16 region with linkage analysis in an Afro-Caribbean (Jamaican) population \[[@r41]\]. In a previous study, we located a region on chr2 (chr2: 46.4M-65.6M) that contributed to POAG with family-linkage analysis studies in Chinese \[[@r22],[@r45]\], which is overlapped with the 2p15-p16 region. A recent study identified a novel missense variant (p.Arg140Trp) in exon 5 of the gene coding for *EFEMP1* that cosegregated with POAG in an African-American family with exome sequencing \[[@r20]\]. In the present POAG cohort, four *EFEMP1* PDVs occurred in six patients with POAG across 235 patients with POAG, while only one subject with one PDV was found in the control group (2.6% versus 0.4%, p = 0.1184, Fisher's exact test). No other potentially disease-relevant variant in the candidate genes was found in the siblings. The results of the family analysis suggested that *EFEMP1* p.Ter494Glu is a potentially disease-causing mutation, although we cannot completely rule out the possibility that other unexamined sources of mutations contribute to POAG symptoms.

![Genetic analysis of a family harboring mutation in *EFEMP1*. Siblings with p.Arg387Gln and p.Ter494Glu of *EFEMP1* gene was shown in **A** and **B**, respectively, with the Integrated Genome Viewer (IGV); the genotype of their parents was identified with Sanger sequencing. **C**, **D**: p.Arg387Gln and p.Ter494Glu for the father of the siblings, respectively. **E**, **F:** p.Arg387Gln and stop signal for the mother of the siblings, respectively. **G**: The pedigree map for the family with mutations in *EFEMP1*.](mv-v26-378-f3){#f3}

This study not only highlighted the discovery of the novel putative disease-relevant variants for POAG but also provided an effective approach for POAG research. In this study, an MIP-based panel sequencing was used to discover POAG disease-relevant variants. The panel enables automatic and low-cost detection for large POAG samples. In addition, new MIPs can be added to the panel to increase the screening regions. We developed a highly efficient protocol for a large number of samples. The cost of reagent and sequencing is about USD20 per sample for the POAG gene screening with this panel (see Appendix 11). Because MIPs can be used 10,000 times once the probes have been synthesized, the cost per sample would greatly decrease as the sample increases. This cost-saving approach has great potential for evaluating the role of each candidate gene by screening large samples and is suitable for use in a routine mutation screening workflow.

A limitation of the present study is the pathogenicity of the PDVs identified in this study mainly based on the prediction of in silico tools. Further verification with function studies, such as animal models, is required. In this study, in silico tools were used to aid in the interpretation of sequence variants. The score of the prediction algorithm is usually based on the alteration of polarity, charge, and evolution conservation of amino acids. The predicted results might provide useful information for estimating the influence of these variants on protein function. However, the prediction of these variations on protein function might be inconsistent with the real context. In general, most algorithms for missense variant prediction are 65--80% accurate when examining known disease variants \[[@r25]\]. A further limitation of this study is that the sample size might not be large enough to detect all possible PDVs showing a statistically significant difference between patients and controls. Thus, these findings should be replicated in additional, larger cohorts. Therefore, additional cohort studies will be valuable for the identification of pathogenic alternations.
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